After being diagnosed with uveal (or ocular) melanoma, Kevin was directed to explore the benefits and indications of Castle Biosciences' DecisionDx®-UM gene expression profile (GEP) test, which predicts a patient’s risk based upon their tumor’s own unique biology. The findings of the test, Kevin says, "were of huge importance to myself and my family. They put me at rest and we could all move on. The Castle uveal melanoma prognostic platform can truly be life-changing."
